Vaccine Response and Immunotherapeutics SWG
- Institution
- Johns Hopkins University, MD
- Principal investigator
- Anna Palmer Durbin
- Funding
- $58K
- Duration
- 2012–2027
Moonbase score
Still being scored
Abstract
The Vaccine Response and Immunotherapeutics (VRI) Scientific Working Group was added to the CFAR in 2021 to foster research related to vaccines and other immunotherapeutics for people living with HIV (PLWH). HIV researchers at JHU recognize the importance of including PLWH in vaccine studies that both are and are not specific to HIV prevention and therapeutics. The immunosuppressive consequences of HIV on the effectiveness and durability of vaccine protection is not well characterized and is an important area of research. Clinical research evaluating the durability and cellular immune responses to childhood and other adult vaccines is critical to determining if current vaccine schedules and recommendations are appropriate for PLWH. This SWG will focus on HIV and non-HIV vaccines and immunotherapeutics for PLWH to promote vaccine science education, foster research interest in vaccines and immunotherapeutics among early- and mid-level faculty, and coordinate with other SWGs to achieve these goals.
LOADING MOONBASE SCORE
Questions for Johns Hopkins University
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Johns Hopkins University72
Development, Piloting and Dissemination of an Integrated Clinical and Social Multi-level Decision Support Platform to Address Social Determinants of Health Among Minority Populations in Baltimore City
Elham Hatef-Naimi · $611K · 2021–2025
- NIH · Johns Hopkins University66
Glucose instability and neurocognitive outcomes in older adults
Elizabeth Selvin · $697K · 2021–2027
- NSF · Johns Hopkins University65
Collaborative Research: CPS: Medium: Data Driven Modeling and Analysis of Energy Conversion Systems -- Manifold Learning and Approximation
Yannis Kevrekidis · $400K · 2023–2026